{"DataElement":{"publicId":"7118727","version":"1","preferredName":"Study Protocol Accrual 10221 Cohort Code","preferredDefinition":"The code that represents the information pertaining to intervention regimen(s), proposed methods for protocol obtaining subjects for a study 10221.","longName":"SDY_PRT_ACC_COH_10221_CD","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"7032260","version":"1","preferredName":"Study Protocol Accrual Cohort Study","preferredDefinition":"A formal document that describes a complete plan of research activity in the framework of a clinical study; specifically, the study objective(s), design, methodology, eligibility requests for prospective subjects and controls; intervention regimen(s), proposed methods of analysis of data; statistical considerations, and organization of the study. The protocol usually also provides the background and rationale for the trial, but these could be represented in other protocol referenced documents._The process of obtaining subjects for a study._A research study that compares a particular outcome (such as lung cancer) in groups of individuals who are alike in many ways but differ by a certain characteristic (for example, female nurses who smoke compared with those who do not smoke).","longName":"2223331v1.0:7032258v1.0","context":"Theradex","contextVersion":"1","ObjectClass":{"publicId":"2223331","version":"1","preferredName":"Protocol","preferredDefinition":"An action plan for a clinical trial.  The plan states what the study will do, how, and why.  It explains how many people will be in it, who is eligible to participate, what study agents or other interventions they will be given, what tests they will receive and how often, and what information will be gathered.","longName":"C25320","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Study Protocol","conceptCode":"C25320","definition":"A formal document that describes a complete plan of research activity in the framework of a clinical study; specifically, the study objective(s), design, methodology, eligibility requests for prospective subjects and controls; intervention regimen(s), proposed methods of analysis of data; statistical considerations, and organization of the study. The protocol usually also provides the background and rationale for the study, but these could be represented in other protocol referenced documents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F62B105A-B8AD-27F8-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-02","endDate":null,"createdBy":"UMLLOADER","dateCreated":"2005-05-02","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7032258","version":"1","preferredName":"Accrual Cohort Study","preferredDefinition":"The process of obtaining subjects for a study.:A research study that compares a particular outcome (such as lung cancer) in groups of individuals who are alike in many ways but differ by a certain characteristic (for example, female nurses who smoke compared with those who do not smoke).","longName":"C25403:C15208","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Accrual","conceptCode":"C25403","definition":"The process of obtaining subjects for a study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cohort Study","conceptCode":"C15208","definition":"A research study that compares a particular outcome (such as lung cancer) in groups of individuals who are alike in many ways but differ by a certain characteristic (for example, female nurses who smoke compared with those who do not smoke).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9600BA80-F277-320D-E053-F662850AD582","latestVersionIndicator":"Yes","beginDate":"2019-10-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-10-29","modifiedBy":"ONEDATA","dateModified":"2019-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9600BA80-F288-320D-E053-F662850AD582","latestVersionIndicator":"Yes","beginDate":"2019-10-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-10-29","modifiedBy":"SOKKERL","dateModified":"2019-11-04","changeDescription":"10/31/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7118718","version":"1","preferredName":"EC 10221 Cohort Code","preferredDefinition":"A group of individuals, identified by a common characteristic._A symbol or combination of symbols which is assigned to the members of a collection.","longName":"7118718v1.0","context":"Theradex","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"250","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Trial 2  Dose Expansion PIK3CA and PTEN Wild Type","valueDescription":"Trial 2  Dose Expansion PIK3CA and PTEN Wild Type","ValueMeaning":{"publicId":"7118719","version":"1","preferredName":"Trial 2  Dose Expansion PIK3CA and PTEN Wild Type","longName":"7118719","preferredDefinition":"Trial 2  Dose Expansion PIK3CA and PTEN Wild Type","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9B2AD1DB-C517-2555-E053-F662850A7843","latestVersionIndicator":"Yes","beginDate":"2020-01-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-01-02","modifiedBy":"ONEDATA","dateModified":"2020-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9B2AD1DB-C530-2555-E053-F662850A7843","beginDate":"2020-01-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-01-02","modifiedBy":"ONEDATA","dateModified":"2020-01-02","deletedIndicator":"No"},{"value":"Trial 2  Dose Expansion PTEN Mutation","valueDescription":"Trial 2  Dose Expansion PTEN Mutation","ValueMeaning":{"publicId":"7118720","version":"1","preferredName":"Trial 2  Dose Expansion PTEN Mutation","longName":"7118720","preferredDefinition":"Trial 2  Dose Expansion PTEN Mutation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9B2AD1DB-C53A-2555-E053-F662850A7843","latestVersionIndicator":"Yes","beginDate":"2020-01-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-01-02","modifiedBy":"ONEDATA","dateModified":"2020-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9B2AD1DB-C553-2555-E053-F662850A7843","beginDate":"2020-01-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-01-02","modifiedBy":"ONEDATA","dateModified":"2020-01-02","deletedIndicator":"No"},{"value":"Trial 2  Dose Expansion PIK3CA Mutation","valueDescription":"Trial 2  Dose Expansion PIK3CA Mutation","ValueMeaning":{"publicId":"7118721","version":"1","preferredName":"Trial 2  Dose Expansion PIK3CA Mutation","longName":"7118721","preferredDefinition":"Trial 2  Dose Expansion PIK3CA Mutation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9B2AD1DB-C55D-2555-E053-F662850A7843","latestVersionIndicator":"Yes","beginDate":"2020-01-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-01-02","modifiedBy":"ONEDATA","dateModified":"2020-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9B2AD1DB-C576-2555-E053-F662850A7843","beginDate":"2020-01-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-01-02","modifiedBy":"ONEDATA","dateModified":"2020-01-02","deletedIndicator":"No"},{"value":"Trial 2  Dose Escalation: Copanlisib 60 mg + Nivolumab + Ipilimumab","valueDescription":"Trial 2  Dose Escalation: Copanlisib 60 mg + Nivolumab + Ipilimumab","ValueMeaning":{"publicId":"7118722","version":"1","preferredName":"Trial 2  Dose Escalation: Copanlisib 60 mg + Nivolumab + Ipilimumab","longName":"7118722","preferredDefinition":"Trial 2  Dose Escalation: Copanlisib 60 mg + Nivolumab + Ipilimumab","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9B2AD1DB-C580-2555-E053-F662850A7843","latestVersionIndicator":"Yes","beginDate":"2020-01-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-01-02","modifiedBy":"ONEDATA","dateModified":"2020-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9B2AD1DB-C599-2555-E053-F662850A7843","beginDate":"2020-01-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-01-02","modifiedBy":"ONEDATA","dateModified":"2020-01-02","deletedIndicator":"No"},{"value":"Trial 2  Dose Escalation: Copanlisib 45 mg + Nivolumab + Ipilimumab","valueDescription":"Trial 2  Dose Escalation: Copanlisib 45 mg + Nivolumab + Ipilimumab","ValueMeaning":{"publicId":"7118723","version":"1","preferredName":"Trial 2  Dose Escalation: Copanlisib 45 mg + Nivolumab + Ipilimumab","longName":"7118723","preferredDefinition":"Trial 2  Dose Escalation: Copanlisib 45 mg + Nivolumab + Ipilimumab","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9B2AD1DB-C5A3-2555-E053-F662850A7843","latestVersionIndicator":"Yes","beginDate":"2020-01-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-01-02","modifiedBy":"ONEDATA","dateModified":"2020-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9B2AD1DB-C5BC-2555-E053-F662850A7843","beginDate":"2020-01-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-01-02","modifiedBy":"ONEDATA","dateModified":"2020-01-02","deletedIndicator":"No"},{"value":"Trial 2  Dose Escalation: Copanlisib 30 mg + Nivolumab + Ipilimumab","valueDescription":"Trial 2  Dose Escalation: Copanlisib 30 mg + Nivolumab + Ipilimumab","ValueMeaning":{"publicId":"7118724","version":"1","preferredName":"Trial 2  Dose Escalation: Copanlisib 30 mg + Nivolumab + Ipilimumab","longName":"7118724","preferredDefinition":"Trial 2  Dose Escalation: Copanlisib 30 mg + Nivolumab + Ipilimumab","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9B2AD1DB-C5C6-2555-E053-F662850A7843","latestVersionIndicator":"Yes","beginDate":"2020-01-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-01-02","modifiedBy":"ONEDATA","dateModified":"2020-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9B2AD1DB-C5DF-2555-E053-F662850A7843","beginDate":"2020-01-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-01-02","modifiedBy":"ONEDATA","dateModified":"2020-01-02","deletedIndicator":"No"},{"value":"Trial 1  (SG3)PIK3CA and PTEN Wild Type","valueDescription":"Trial 1  (SG3)PIK3CA and PTEN Wild Type","ValueMeaning":{"publicId":"7118725","version":"1","preferredName":"Trial 1  (SG3)PIK3CA and PTEN Wild Type","longName":"7118725","preferredDefinition":"Trial 1  (SG3)PIK3CA and PTEN Wild Type","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9B2AD1DB-C5E9-2555-E053-F662850A7843","latestVersionIndicator":"Yes","beginDate":"2020-01-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-01-02","modifiedBy":"ONEDATA","dateModified":"2020-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9B2AD1DB-C602-2555-E053-F662850A7843","beginDate":"2020-01-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-01-02","modifiedBy":"ONEDATA","dateModified":"2020-01-02","deletedIndicator":"No"},{"value":"Trial 1  (SG2)PTEN Mutation","valueDescription":"Trial 1  (SG2)PTEN Mutation","ValueMeaning":{"publicId":"7118726","version":"1","preferredName":"Trial 1  (SG2)PTEN Mutation","longName":"7118726","preferredDefinition":"Trial 1  (SG2)PTEN Mutation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9B2AD1DB-C60C-2555-E053-F662850A7843","latestVersionIndicator":"Yes","beginDate":"2020-01-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-01-02","modifiedBy":"ONEDATA","dateModified":"2020-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9B2AD1DB-C625-2555-E053-F662850A7843","beginDate":"2020-01-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-01-02","modifiedBy":"ONEDATA","dateModified":"2020-01-02","deletedIndicator":"No"},{"value":"Trial 1  (SG1)PIK3CA Mutation","valueDescription":"Trial 1  (SG1)PIK3CA Mutation","ValueMeaning":{"publicId":"7092660","version":"1","preferredName":"Trial 1  (SG1)PIK3CA Mutation","longName":"7092660","preferredDefinition":"Trial 1  (SG1)PIK3CA Mutation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"99D4EFF4-A056-546B-E053-F662850AA313","latestVersionIndicator":"Yes","beginDate":"2019-12-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9B2AD1DB-C639-2555-E053-F662850A7843","beginDate":"2020-01-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-01-02","modifiedBy":"ONEDATA","dateModified":"2020-01-02","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"4386398","version":"1","preferredName":"Cohort Code","preferredDefinition":"A group of individuals, identified by a common characteristic.:A system of numbered categories for representation of data.","longName":"C61512:C25162","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cohort","conceptCode":"C61512","definition":"A group of individuals, identified by a common characteristic.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE558C16-1C27-C6A8-E040-BB89AD430BEE","latestVersionIndicator":"Yes","beginDate":"2014-07-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-07-16","modifiedBy":"ONEDATA","dateModified":"2014-07-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9B2AD1DB-C4FF-2555-E053-F662850A7843","latestVersionIndicator":"Yes","beginDate":"2020-01-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-01-02","modifiedBy":"SOKKERL","dateModified":"2020-01-02","changeDescription":"1/02/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Please select the accrual coh","type":"Preferred Question Text","description":"Please select the accrual cohort","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9B2AE117-9FCC-201F-E053-F662850A5859","latestVersionIndicator":"Yes","beginDate":"2020-01-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-01-02","modifiedBy":"SOKKERL","dateModified":"2020-01-02","changeDescription":"1/2/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}